JIP
PRME icon

Jaffetilchin Investment Partners’s Prime Medicine PRME Stock Holding History

Jaffetilchin Investment Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,744
Closed -$93.2K – 459
2025
Q2 		$93.2K Buy
+37,744
New +$58.2K 0.01% 425

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jaffetilchin Investment Partners's PRME Position: Q3 2025 in Review

Jaffetilchin Investment Partners sold out of Prime Medicine (PRME) in Q3 2025, closing a stake of 37,744 shares — an estimated $93.2K sold.

Jaffetilchin Investment Partners first reported a position in PRME in Q2 2025 and held it in 1 quarter. The position peaked at $93.2K in Q2 2025. 167 funds tracked by Wall St. Rank hold PRME as of Q3 2025.

  • Jaffetilchin Investment Partners reported no remaining Prime Medicine position as of Q3 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 37,744 Prime Medicine shares in Q3 2025, an estimated $93.2K.
  • Jaffetilchin Investment Partners first reported a position in Prime Medicine in Q2 2025 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Prime Medicine position peaked at $93.2K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2025, filed 13 Nov 2025.